Lindbrook Capital’s Harmony Biosciences HRMY Stock Holding History

Lindbrook Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$6.34K	Buy	191 +28	+17%	+$1K	﹤0.01%	1858
2024 Q4	$5.61K	Sell	163 -8	-5%	-$275	﹤0.01%	1931
2024 Q3	$6.84K	Sell	171 -9	-5%	-$316	﹤0.01%	1872
2024 Q2	$5.43K	Buy	180 +48	+36%	+$1.44K	﹤0.01%	1956
2024 Q1	$4.43K	Hold	132	–	–	﹤0.01%	1946
2023 Q4	$4.26K	Buy	+132	New	+$3.68K	﹤0.01%	1968
2023 Q3	–	Sell	-11	Closed	-$387	–	2749
2023 Q2	$387	Buy	+11	New	+$380	﹤0.01%	2558
2023 Q1	–	Sell	-76	Closed	-$4.19K	–	2836
2022 Q4	$4.19K	Sell	76 -61	-45%	-$3.35K	﹤0.01%	1911
2022 Q3	$6K	Buy	137 +132	+2,640%	+$6.44K	﹤0.01%	1559
2022 Q2	$0	Buy	+5	New	+$225	﹤0.01%	2594

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lindbrook Capital's HRMY Position: Q1 2025 in Review

Lindbrook Capital increased its Harmony Biosciences (HRMY) stake by 17% in Q1 2025, buying an estimated $1K and bringing the position to 191 shares worth $6.34K. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Lindbrook Capital first reported a position in HRMY in Q2 2022 and has held it in 10 quarters since. The position peaked at $6.84K in Q3 2024. 272 funds tracked by Wall St. Rank hold HRMY as of Q1 2025.

Lindbrook Capital held 191 shares of Harmony Biosciences worth $6.34K as of Q1 2025.
Lindbrook Capital bought 28 Harmony Biosciences shares in Q1 2025, an estimated $1K.
Harmony Biosciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1858 holding.
Lindbrook Capital first reported a position in Harmony Biosciences in Q2 2022 and has held it in 10 quarters since.
Lindbrook Capital's Harmony Biosciences position peaked at $6.84K in Q3 2024.
272 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.